Johnson & Johnson (JNJ)

125.03
NYSE : Health Care
Prev Close 125.15
Day Low/High 124.64 / 125.35
52 Wk Low/High 81.79 / 126.07
Avg Volume 7.10M
Exchange NYSE
Shares Outstanding 2.75B
Market Cap 344.24B
EPS 5.60
P/E Ratio 22.80
Div & Yield 3.20 (2.60%)

Latest News

Don't Disrespect This Bull Market

Don't Disrespect This Bull Market

There are plenty of doubters about the market and its record highs.

Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank

Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank

Deutsche Bank upped its price target on Johnson & Johnson (JNJ) stock to $142 from $125 on Thursday morning.

10 Best Dividend Stocks to Own Now for a Safe Retirement

10 Best Dividend Stocks to Own Now for a Safe Retirement

These blue-chip stocks pay safe, generous dividends and form the foundation of a sturdy retirement portfolio.

Valeant's Drug Approvals May Save the Day

Valeant's Drug Approvals May Save the Day

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

3 Compelling Reasons to Buy Johnson & Johnson Following Earnings

3 Compelling Reasons to Buy Johnson & Johnson Following Earnings

This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are rising Wednesday, setting up the Dow Jones Industrial Average for its seventh record close in a row.

Can Johnson & Johnson Keep Soaring Higher?

Can Johnson & Johnson Keep Soaring Higher?

Near-time upside for Johnson & Johnson could be limited.

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Johnson & Johnson Boosts Dow, Netflix Pressures the S&P 500

Johnson & Johnson Boosts Dow, Netflix Pressures the S&P 500

It was the tale of two earnings seasons on Tuesday and Wall Street was stuck in the middle.

Closing Bell: S&P Cuts Outlook on Deutsche; Dow Seals New Record

Closing Bell: S&P Cuts Outlook on Deutsche; Dow Seals New Record

Better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record.

Stocks Fluctuate as Johnson & Johnson Climbs, Netflix Shares Tumble

Stocks Fluctuate as Johnson & Johnson Climbs, Netflix Shares Tumble

Stocks fluctuate late Tuesday as earnings reports are mixed.

Johnson & Johnson Hits Record High Despite Declines in Baby Care

Johnson & Johnson Hits Record High Despite Declines in Baby Care

The pharmaceutical giant hits record high on better-than-expected second quarter earnings.

Johnson & Johnson (JNJ) Stock Rises, CFO Talks M&A

Johnson & Johnson (JNJ) Stock Rises, CFO Talks M&A

Johnson & Johnson (JNJ) shares are increasing in afternoon trading today as company CFO Caruso discusses possible mergers.

Cramer: In Earnings Tests, JNJ Gets an A While Netflix Flunks

Cramer: In Earnings Tests, JNJ Gets an A While Netflix Flunks

It depends on the type of test and who's doing the grading.

Midday Report: Monsanto Rebuffs Bayer Again; S&P 500 Declines

Midday Report: Monsanto Rebuffs Bayer Again; S&P 500 Declines

A rush of earnings kept investors busy throughout the morning. Netflix was one of the biggest drags on the Nasdaq and S&P 500.

Johnson & Johnson Has an Impressive Growth Story, Says Jim Cramer

Johnson & Johnson Has an Impressive Growth Story, Says Jim Cramer

Johnson & Johnson's earnings reveal just how impressive growth is at the big pharma company, according to Jim Cramer.

Johnson & Johnson Tops Earnings Estimates

Johnson & Johnson Tops Earnings Estimates

The health care giant's quarterly earnings and sales clocked in well above analyst expectations.

Dow Trades Flat After Johnson & Johnson Quarterly Beat

Dow Trades Flat After Johnson & Johnson Quarterly Beat

Stocks are off session lows by mid-morning Tuesday with the Dow Jones Industrial Average trying for gains after a rush of key earnings.

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer is impressed by Johnson & Johnson's continual growth.

Johnson & Johnson (JNJ) CFO Caruso Is 'Very Happy With Results' He Tells CNBC

Johnson & Johnson (JNJ) CFO Caruso Is 'Very Happy With Results' He Tells CNBC

Johnson& Johnson (JNJ) reported better than anticipated earnings Tuesday morning before the opening bell, CFO Dominic Caruso joined CNBC's "Squawk Box" to discuss the report.

Ortho Clinical Diagnostics Receives Coveted #1 Ranking For Service Performance

Ortho Clinical Diagnostics Receives Coveted #1 Ranking For Service Performance

In Vitro Diagnostics Industry Rankings Published by ServiceTrak™

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are pointing lower Tuesday ahead of a full slate of earnings reports.

Stock Futures Hold Lower as Housing Starts Climb

Stock Futures Hold Lower as Housing Starts Climb

Stock futures are slightly lower on Tuesday as key earnings from the likes of Netflix disappoint investors, while housing starts edge forward.

Morning Movers: NFLX, JNJ, VMW, GES

Morning Movers: NFLX, JNJ, VMW, GES

Netflix underwhelmed analysts as subscriber growth came up short.

Johnson & Johnson Lifts Full-Year Outlook as It Tops Quarterly Forecasts

Johnson & Johnson Lifts Full-Year Outlook as It Tops Quarterly Forecasts

Pharmaceuticals sales once again drive growth in the health care group's second quarter.

What to Watch Tuesday: Goldman Sachs Earnings, June Housing Starts

What to Watch Tuesday: Goldman Sachs Earnings, June Housing Starts

On Tuesday, July 19, investors will focus on the U.S. banking sector when Goldman Sachs reports second quarter results.